Dr. Moore is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
13400 E Shea Blvd
Scottsdale, AZ 85259Phone+1 480-301-8000Fax+1 919-852-0321
Summary
- Dr. Cassandra Moore is an oncologist based in Scottsdale, AZ, with subspecialty expertise in genitourinary oncology. She completed her medical education at the University of New Mexico School of Medicine and pursued residency in internal medicine at UMass Chan Medical School followed by a fellowship in hematology and medical oncology at Duke University Hospital. Currently, she serves as a Senior Associate Consultant at Mayo Clinic Hospital, having previously been the Lead Physician at Banner MD Anderson Cancer Center. Dr. Moore is experienced in treating various genitourinary cancers, including prostate, kidney, bladder, and testicular cancer. She has contributed to several publications related to prostate cancer and participated in clinical trials such as the GEN1046 Safety Trial in patients with malignant solid tumors.
Education & Training
- Duke University HospitalFellowship, Hematology and Medical Oncology, 2003 - 2006
- UMass Chan Medical SchoolResidency, Internal Medicine, 1999 - 2002
- University of New Mexico School of MedicineClass of 1999
Certifications & Licensure
- AZ State Medical License 2015 - 2026
- GA State Medical License 2024 - 2026
- NH State Medical License 2024 - 2026
- TN State Medical License 2024 - 2026
- CO State Medical License 2024 - 2025
- LA State Medical License 2024 - 2025
- MN State Medical License 2024 - 2025
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- GEN1046 Safety Trial in Patients With Malignant Solid Tumors Start of enrollment: 2019 May 14
Publications & Presentations
PubMed
- 7 citationsThe impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.Alex J Liu, Heidi E Kosiorek, Benjamin E Ueberroth, Ellen Jaeger, Elisa Ledet
The Prostate. 2022-09-01 - 24 citationsDifferential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer.Miguel Gonzalez Velez, Heidi E. Kosiorek, Jan B. Egan, Andrea McNatty, Irbaz Bin Riaz
Prostate Cancer and Prostatic Diseases. 2021-07-22 - 1 citationsEvolving Natural History of Metastatic Prostate Cancer.Nellie Nafissi, Heidi E. Kosiorek, Richard J. Butterfield, Cassandra N. Moore, Thai H. Ho
Cureus. 2020-11-14
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: